News
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...
Eli Lilly CEO David Ricks bought just over $1 million of Lilly shares in the open market Tuesday following the sharp drop in ...
Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets ...
Eli Lilly has launched pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving more options for those ...
Eli Lilly specializes in obesity and diabetes treatments, among other areas. It's reasonable to expect a lot more growth from ...
19h
TipRanks on MSNEli Lilly’s Orforglipron Study: A New Hope for Obesity Treatment?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company recently completed a ...
(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...
The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...
Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...
22h
Global News - Inquirer.net on MSNWill China’s home-grown obesity drugs reshape global weight loss market?
July, video editor Meng Meng, 38, has been injecting herself with a weekly weight loss drug, hoping it will finally help her shed the weight she has long struggled with. Standing at 1.63m tall and ...
Eli Lilly introduces its Mounjaro Kwikpen in India at ₹14,000 for the 2.5 mg starting dose, competing with Novo Nordisk’s Wegovy in the booming GLP-1 drug market for diabetes and weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results